EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B

S J Hume iD, K Visvanathan iD, K Cheng, K Jackson, S Vogrin iD, S A L Hall iD, G S Burns, P V Desmond, D Ratnam, M T Levy, R Sawhney iD, S I Strasser iD und 11 weitere

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiaf569 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von S J Hume und 22 weiteren Autor:innen. Beteiligte Einrichtung: St Vincent's Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B Surface Antigens, Antiviral Agents, Antigen-Antibody Complex. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health and Medical Research Council of Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Humoral immunity is thought to play a key role in the immunopathogenesis of chronic hepatitis B (CHB). Peaks in anti-HBs immune complexes (HBsAg-ICs) have been associated with subsequent HBsAg seroclearance. Discontinuation of nucleos(t)ide analog (NA) therapy can promote HBsAg seroclearance but also carries a risk of hepatitis flare. We evaluated the relationship between serum HBsAg-IC levels and hepatitis flare following NA cessation in HBeAg-negative CHB.

Methods

In a multicentre prospective cohort of noncirrhotic HBeAg-negative CHB patients undergoing NA discontinuation, we conducted a nested case-control analysis (n = 38). Stored serum samples were tested for HBsAg-IC at end-of-treatment (EOT) and at serial timepoints off-treatment. Cases (n = 24) experienced a hepatitis flare (ALT >5× upper limit of normal); controls (n = 14) did not. Associations between HBsAg-IC levels and clinical outcomes were analyzed.

Results

Serum HBsAg-ICs were detectable in 97% of participants at EOT. High HBsAg-IC levels (≥40 IU/mL) at EOT were less frequent among those who developed hepatitis flare (8%) versus controls (57%, P = .002). Individuals treated with tenofovir (vs other NAs) had lower EOT HBsAg-IC levels. Longitudinal analysis revealed dynamic increases in HBsAg-IC levels during hepatitis flare, peaking with maximal ALT. Participants who experienced beneficial flares (≥1 log₁₀ HBsAg reduction) had higher peak off-treatment HBsAg-IC levels compared to those with nonbeneficial flares.

Conclusions

Serum HBsAg-ICs are detectable in patients with CHB, and low levels at EOT are associated with the risk of hepatitis flare after NA cessation. These findings support the role of humoral immunity in CHB immunopathogenesis. Clinical Trials Registration The study clinical trial ID is NCT02581033.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicHepatitis B Surface AntigensAntiviral AgentsAntigen-Antibody ComplexNucleosidesHepatitis B AntibodiesHumansMaleFemaleAdultProspective StudiesCase-Control StudiesMiddle AgedHepatitis B e AntigensBiomarkers

Stichwörter der Autor:innen

biomarkerchronic hepatitis Bhepatitis flareimmune complexesnucleos(t)ide analog withdrawal

Substanzen

Hepatitis B Surface AntigensAntiviral AgentsHepatitis B e AntigensBiomarkersAntigen-Antibody ComplexNucleosidesHepatitis B Antibodies

Autor:innen und Institutionen

  • St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Department of Medicine, The University of Melbourne, Victoria, Australia.
  • Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Western Health, Melbourne, Victoria, Australia.
  • Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia.
  • Liverpool Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: S J Hume, K Visvanathan, S Vogrin, S A L Hall, R Sawhney, S I Strasser, D Wong, M Littlejohn, N Warner

Förderung

  • National Health and Medical Research Council of Australia

Zitieren

APA

Hume, S. J., Visvanathan, K., Cheng, K., Jackson, K., Vogrin, S., Hall, S. A. L., Burns, G. S., Desmond, P. V., Ratnam, D., Levy, M. T., Sawhney, R., Strasser, S. I., Ngu, M. C., Sinclair, M., Meredith, C., Matthews, G., Valaydon, Z., Wong, D., Littlejohn, M., …, & Warner, N. (2026). Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf569

Vancouver

Hume SJ, Visvanathan K, Cheng K, Jackson K, Vogrin S, Hall SAL, et al. Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiaf569

BibTeX
@article{Hume2026,
  author = {Hume, S J and Visvanathan, K and Cheng, K and Jackson, K and Vogrin, S and Hall, S A L and Burns, G S and Desmond, P V and Ratnam, D and Levy, M T and Sawhney, R and Strasser, S I and Ngu, M C and Sinclair, M and Meredith, C and Matthews, G and Valaydon, Z and Wong, D and Littlejohn, M and Holmes, J A and Revill, P A and Thompson, A J and Warner, N},
  title = {Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiaf569}
}
Kostenlos starten →